Compare RNW & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | GLPG |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United Kingdom | Belgium |
| Employees | 4336 | 704 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | N/A | N/A |
| Metric | RNW | GLPG |
|---|---|---|
| Price | $5.32 | $32.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 640.2K | 109.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.97 | N/A |
| P/E Ratio | $14.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.05 | $22.59 |
| 52 Week High | $8.24 | $37.78 |
| Indicator | RNW | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 44.96 |
| Support Level | $5.27 | $31.88 |
| Resistance Level | $5.63 | $33.67 |
| Average True Range (ATR) | 0.13 | 0.71 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 39.11 | 34.20 |
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.